Back to top
more

Merck & Co. (MRK)

(Real Time Quote from BATS)

$107.00 USD

107.00
4,386,467

-1.70 (-1.56%)

Updated Oct 21, 2024 02:38 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 14% (34 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Biotech Stock Roundup: BMY's Q3 Earnings Beat, MRNA's Vaccine Updates & More

by Zacks Equity Research

Earnings and other updates from bigwigs like Bristol Myers (BMY) and Moderna (MRNA) have been the biotech sector's few key highlights during the past week.

Will Pfizer (PFE) Keep the Earnings Streak Alive in Q3?

by Zacks Equity Research

Higher sales of Pfizer's (PFE) key brands, Ibrance, Eliquis and Inlyta, and revenues from the COVID-19 vaccine are likely to have driven sales in the third quarter.

Should You Buy Merck & Co. (MRK) Ahead of Earnings?

by Zacks Equity Research

Merck & Co. (MRK) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Should You Invest in the Invesco Dynamic Pharmaceuticals ETF (PJP)?

by Zacks Equity Research

Sector ETF report for PJP

Benjamin Rains headshot

Buy This Great High-Yield Dividend Stock?

by Benjamin Rains

Investors in search of stable income should consider strong dividend-paying stocks, with solid yields. Pharmaceutical standout AbbVie appears to be worth buying as a long-term play, with it set to release its Q3 results on Friday, October 29...

Merck (MRK) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda, when the company reports Q3 earnings.

Kinjel Shah headshot

Pharma Stock Roundup: JNJ Mixed Q3 Results, FDA Nod to Mix & Match COVID Boosters

by Kinjel Shah

J&J (JNJ) beats estimates for earnings but misses the same for sales. FDA authorizes mix and match of COVID vaccine boosters.

Merck (MRK) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Merck (MRK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The Zacks Analyst Blog Highlights: Microsoft, Mastercard, Pfizer, PepsiCo and Merck

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Microsoft, Mastercard, Pfizer, PepsiCo and Merck

Will Eli Lilly (LLY) Surpass Q3 Earnings Expectations?

by Zacks Equity Research

Higher demand for its key drugs is likely to have offset generic competition for several other drugs and may have boosted Lilly's (LLY) third-quarter sales.

Roche's (RHHBY) Tecentriq Gets FDA Nod for Another Indication (Revised)

by Zacks Equity Research

Roche (RHHBY) immuno-oncology drug Tecentriq gets FDA approval for yet another indication of lung cancer.

Merck (MRK) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

Merck (MRK) closed at $81.07 in the latest trading session, marking a +1.99% move from the prior day.

Sheraz Mian headshot

Top Analyst Reports for Microsoft, Mastercard & Pfizer

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corporation (MSFT), Mastercard Incorporated (MA), and Pfizer Inc. (PFE).

Atea (AVIR) Plunges on Oral COVID Candidate Study Failure

by Zacks Equity Research

Atea (AVIR) is developing an oral drug candidate, AT-527, as a potential treatment for COVID-19 in outpatients as well as hospitalized settings in several studies.

    Biogen (BIIB) Q3 Earnings Top, Aduhelm Sales Negligible

    by Zacks Equity Research

    Biogen (BIIB) beats third-quarter estimates for both earnings and sales and ups its financial guidance for 2021.

      Stock Market News for Oct 20, 2021

      by Zacks Equity Research

      The S&P 500 and Nasdaq recoded the largest four consecutive winning stretch since July, lifted by an encouraging third-quarter corporate earnings result.

      Esperion (ESPR) to Cut 40% Workforce, Revamp Cost Structure

      by Zacks Equity Research

      Esperion (ESPR) is set reduce its workforce by 40% and start targeted program savings to reduce its operational expense and deliver consistent growth.

      J&J (JNJ) Beats on Q3 Earnings, Misses on Sales, Ups EPS View

      by Zacks Equity Research

      J&J (JNJ) reports mixed third-quarter earnings. It beats estimates for earnings but misses the same for sales. It raises its earnings guidance range for the year.

      Gilead's (GILD) Biktarvy Gets FDA Nod for Pediatric Patients

      by Zacks Equity Research

      Gilead (GILD) wins FDA approval for the label expansion of HIV treatment Biktarvy for the pediatric patient population.

      Gilead (GILD) Breast Cancer Drug Gets Positive CHMP Opinion

      by Zacks Equity Research

      Gilead's (GILD) application for breast cancer drug gets positive opinion for approval from EMA's CHMP.

      Roche's (RHHBY) Tecentriq Gets FDA Nod for Another Indication

      by Zacks Equity Research

      Roche (RHHBY) immuno-oncology drug Tecentriq gets FDA approval for yet another indication of lung cancer.

      J&J (JNJ) to Start Q3 Earnings Season for Pharma Sector

      by Zacks Equity Research

      J&J's (JNJ) Pharma segment is expected to have performed above market while market recovery might have benefited Medical Devices segment sales in the third quarter.

      Clovis (CLVS) Focuses on Rubraca Growth Amid Rising Competition

      by Zacks Equity Research

      Clovis Oncology's (CLVS) sole marketed drug Rubraca has been approved for multiple cancer indications. Yet, the drug's sales remain tepid on account of competition from PARP inhibitors.

      Merck (MRK) Stock Sinks As Market Gains: What You Should Know

      by Zacks Equity Research

      In the latest trading session, Merck (MRK) closed at $78.33, marking a -0.79% move from the previous day.

      Merck (MRK) Seeks Emergency Nod for Oral Antiviral COVID-19 Pill

      by Zacks Equity Research

      Merck's (MRK) molnupiravir to be the first oral antiviral medicine for the treatment of COVID-19, if authorized by the FDA.